BioCryst Pharmaceuticals, Inc. (BCRX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema.
Is BioCryst Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at $8.47 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: BioCryst Pharmaceuticals, Inc.
Market cap $2B · 52 weeks $6 – $11 (24 % below the high) · P/E no earnings · 2027 expected P/E 15.2× · Dividend none · Next earnings November 4, 2026 · expected EPS $0.09 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/Sales 2.0× (no earnings).
- Balance sheet: Grey zone (watch).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 1 of 4 pass
- Market cap / Cash 6.5×, fails.
- Total Debt 1.9×, borderline.
- R&D / Market cap 9.3 %, borderline.
- Annual cash burn $1.57, passes.
Against its peers (reference peers) — BioCryst Pharmaceuticals, Inc.: P/E —; EV/EBITDA —; ROIC -89.0 %; $2.2B. Aurinia Pharmaceuticals Inc. (P/E 7.3×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.2B), Lakefront Biotherapeutics N.V. (P/E 3.9×; EV/EBITDA 5.3×; ROIC 11.6 %; $2.1B), Harmony Biosciences Holdings, Inc. (P/E 12.6×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.3B).
Profitability
| Return on Equity | 101.55% |
| Return on Invested Capital | -88.96% |
| Return on Assets | -68.96% |
| Gross Margin | 23.52% |
| Operating Margin | -33.29% |
| Net Margin | -40.90% |
Financial Health
| Debt / Equity | -0.90 |
| Current Ratio | 2.32 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.83 |
Price Performance
| 1 month | +3.67% |
| 3 months | -3.86% |
| Year-to-date | +8.59% |
| 1 year | +15.71% |
| 3 years | +50.18% |
| 5 years | -44.06% |
| 10 years | +125.27% |
Related companies: PHVS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of BCRX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks